Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004048 · ClinicalTrials.gov registry record · Phase 1

Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer

A Phase 1 study of Head and Neck Cancer, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT00004048 is a Phase 1 study of Head and Neck Cancer that has completed, run by Garden State Cancer Center at the Center for Molecular Medicine and Immunology. The registered enrollment target is 30 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004048, a Phase 1 study of Head and Neck Cancer, has completed, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by radioimmunotherapy or chemotherapy used to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radioimmunotherapy with or without doxorubicin plus peripheral stem cell transplantation in treating patients who have thyroid cancer.

Conditions Studied

Head and Neck Cancer

Interventions

  • PROCEDURE peripheral blood stem cell transplantation
  • BIOLOGICAL filgrastim
  • DRUG doxorubicin hydrochloride
  • PROCEDURE autologous bone marrow transplantation
  • RADIATION indium In 111 monoclonal antibody MN-14

Study Locations (2)

New Jersey

  • Garden State Cancer Center - Belleville
  • St. Joseph's Hospital and Medical Center - Paterson

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 1998-09
Est. Completion 2002-05
Phase Phase 1

Sponsor

Garden State Cancer Center at the Center for Molecular Medicine and Immunology

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00004048

The ClinicalTrials.gov registry entry for NCT00004048 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Garden State Cancer Center at the Center for Molecular Medicine and Immunology, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 5 interventions - of which peripheral blood stem cell transplantation is the first listed.

NCT00004048 reports 2 study locations spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT00004048 about?

NCT00004048 is a clinical study titled "Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace ...

What is the current status of trial NCT00004048?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1998-09. Estimated completion is 2002-05.

What conditions does trial NCT00004048 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT00004048?

The interventions under investigation include: peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), autologous bone marrow transplantation (PROCEDURE), indium In 111 monoclonal antibody MN-14 (RADIATION).

Who is sponsoring clinical trial NCT00004048?

This trial is sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004048 being conducted?

This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.